Received Jan 21, 2026
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| RV5 | ROTAVIRUS (ROTATEQ) | MERCK & CO. INC. | 3 | Z009673 | OT |
No adverse effects were reported/No additional AE; a child was administered the 3rd dose of ROTATEQ after the 32 week (8 months of age) limit/Child was aged 9 months at the time of administration of the 3rd dose; This Spontaneous report was received from a nurse and referred to a 9 months (also reported as child) patient of unknown gender. The patient's medical history was not reported. The patient's past medications were not reported. The patient's concomitant medications were not reported. On 19-Jan-2026, the patient was vaccinated with the 3rd dose of Rotavirus Vaccine, Live, Oral, Pentavalent (ROTATEQ), 2.00 mL, route default to oral, Lot Number: Z009673, Expiration date: 23-Dec-2026, strength reported as 2 (unit not provided) (frequency was not reported) for prophylaxis, after the 32 week (8 months of age) limit for administration. The patient was aged 9 months at the time of administration of the 3rd dose. No adverse effects were reported. No additional adverse event (AE)/No product quality complaints (PQC).